PROFILE
MORIMOTO Chikao, M.D., Ph.D.
Department of Therapy Development and Innovation for Immune Disorders and Cancers
Short Biography
- 1973
- M.D. Keio University School of Medicine
- 1978
- Ph.D. Keio University School of Medicine
- 1982-1988
- Assistant Professor, Harvard Medical School
- 1988-1995
- Associate Professor, Harvard Medical School
- 1995-2012
- Professor, The Institute of Medical Science, The University of Tokyo
- 2008-2012
- Director, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo
- 2012-Present
- Professor and Chairman, Department of Therapy Development and Innovation for Immune Disorders and Cancers, Juntendo University Graduate School of Medicine
Professor Emeritus, The University of Tokyo
Keywords
- CD26/DPP4
- IL-26
- Antibody Therapeutic
- Malignant Pleural Mesothelioma
- Translational Research
Main Research Topics and Interests
- The mechanism of action for anti-tumor activity of humanized anti-CD26 monoclonal antibody
- Development of biomarkers for the prognosis of cancer therapy by humanized anti-CD26 monoclonal antibody
- Analyses of novel biological functions of inflammatory cytokine IL-26
- Development of a novel IL-26-targeted therapy for refractory autoimmune diseases and cancers
Publications (in English)
- Original Articles: 330
- Review Articles: 40
- Books: 33
- h-Index: 78 (Scopus)
- Sum of Times Cited: 20,421 (Scopus)
Recent Main Publications
- Cell Death Dis. 2021; 12(6): 520
- Nat Med. 2020; 26(9): 1480-1490
- Lung Cancer 2019; 137: 64-70
- More
Other Specific Comments
Award and Honors
- 2011 Highly Cited Researcher for Immunology (Thomson ISI) (2000-2010)
Link
